Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...

GlobalData’s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...